Press Releases from Genekam Biotechnology AG (4 total)
World Innovation: First therapeutic molecule candidate against Zika viruses
Genekam Biotechnology AG, which developed the first test for Zikavrius detection in Januar 2016, has developed as one of first company in the world the therapeutic molecule candidate for Zika viruses, which is likely to be the first potential candidate for Zika-virus therapy.
Zika viruses are known to cause fears as they infect pregnant women leading to disorders and new born with microencephaly (child with smaller head) with whole life handicap…
DNA-FluHunter - The all-rounder weapon against bird flu virus
First commercial DNA-Test worldwide to detect all pathogenic strains of bird flu H5, N1, H9 and H7.
Duisburg, July 31 2007: Genekam Biotechnology AG has now developed the first commercial DNA-Test of the world to detect all dangerous types of bird flu H5, N1, H7, H9. These stocks lead to disease and death in both human and animals. Especially H5 and H7 are aggressive to birds, leading to mortality and economical…
DNA Fluhunter - First commercial DNA-Test worldwide to detects all pathogenic st …
Duisburg 22. Dezember 2005 Genekam Biotechnology AG has now developed the first commercial DNA-Test of the world to detect all dangerous types of bird flu H5, N1, H7, H9. These stocks lead to disease and death in both human and animals. Especially H5 and H7 are aggressive to birds, leading to mortality and economical losses in a short time.
DNA-tests have the particular feature to be most reliable, accurate…
First worldwide commercial DNA Test for H5N1 and H9 to detect avian influenza vi …
Genekam Bird flu DNA-Test (H5N1, H9)
Duisburg, December 7th, 2005
With help of modern technology, German’s molecular medicine company Genekam did a good job on developing a most reliable and accurate DNA-based test that is able to detect the avian influenza virus H5N1 along with the not less dangerous H9 virus in a very short time. This DNA test is not only reliable and most accurate. It can be performed under…
